CLDN1 and glioblastoma: Increased expression of DSG3 (HR 1.36, 95% confidence interval (CI) 1.11–1.67, p = 0.004), FN1 (HR 1.29, 95% CI 1.08–1.56, p = 0.006), IGFBP2 (HR 1.18, 95% CI 1.04–1.35, p = 0.011), CLDN1 (HR 1.24, 95% CI 1.05–1.46, p = 0.013), HDAC7 (HR 1.36, 95% CI 1.04–1.77, p = 0.023), and L1CAM (HR 1.10, 95% CI 1.01–1.19, p = 0.024) were associated with poor prognoses of glioblastoma (Figure S2a–f).